Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function
Foster GG, Grant MJ, Thomas SM, Cameron B, Raiff D, Corbet K, Loitsch G, Ferreri C, Horwitz M. Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function. Transplantation And Cellular Therapy 2020, 26: 1597-1606. PMID: 32450288, PMCID: PMC8026759, DOI: 10.1016/j.bbmt.2020.05.007.Peer-Reviewed Original ResearchConceptsAllogeneic hematopoietic cell transplantHematopoietic cell transplantChronic kidney diseaseRenal functionFoscarnet treatmentCell transplantHuman herpes virus-6 (HHV-6) reactivationLong-term renal functionAcute kidney injuryAcute kidney failureTransplant-related factorsAllo-HCTFoscarnet useMedian eGFRsKidney injuryAdult patientsFrequent indicationKidney diseaseKidney failureFoscarnetAnti-infective agentsMultivariate analysisPatientsOptimal managementMonths